Intestinal cells protect us from harmful bacteria by forming a physical barrier and raising immune danger signals when needed. This research reveals a nuclear “knight” molecule that suppresses unnecessary immune activation during metabolic stress, helping maintain intestinal health and preventing excessive inflammation.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.